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Abstract
Background: This nationwide study assessed the impact of nationally agreed cancer genetics guidelines on use of
BRCA1/2 germline testing, risk management advice given by health professionals to women with pathogenic
BRCA1/2 variants and uptake of such advice by patients.
Methods: Clinic files of 883 women who had initial proband screens for BRCA1/2 pathogenic variants at 12 familial
cancer clinics between July 2008–July 2009 (i.e. before guideline release), July 2010–July 2011 and July 2012–July
2013 (both after guideline release) were audited to determine reason given for genetic testing. Separately, the clinic
files of 599 female carriers without a personal history of breast/ovarian cancer who underwent BRCA1/2 predictive
genetic testing and received their results pre- and post-guideline were audited to ascertain the risk management
advice given by health professionals. Carriers included in this audit were invited to participate in a telephone
interview to assess uptake of advice, and 329 agreed to participate.
Results: There were no significant changes in the percentages of tested patients meeting at least one published
indication for genetic testing - 79, 77 and 78% of files met criteria before guideline, and two-, and four-years post-
guideline, respectively (χ = 0.25, p = 0.88). Rates of documentation of post-test risk management advice as per
guidelines increased significantly from pre- to post-guideline for 6/9 risk management strategies. The strategies with
the highest compliance amongst carriers or awareness post-release of guidelines were annual magnetic resonance
imaging plus mammography in women 30–50 years (97%) and annual mammography in women > 50 years (92%).
Of women aged over 40 years, 41% had a risk-reducing bilateral mastectomy. Amongst women aged > 40 years,
75% had a risk-reducing salpingo-oophorectomy. Amongst women who had not had a risk-reducing bilateral
mastectomy, only 6% took risk-reducing medication. Fear of side-effects was cited as the main reasons for not
taking these medicines by 73% of women.
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Conclusions: Guidelines did not change the percentages of tested patients meeting genetic testing criteria but
improved documentation of risk management advice by health professionals. Effective approaches to enhance
compliance with guidelines are needed to improve risk management and quality of care.
Keywords: Guidelines, Compliance, Genetic testing, Cancer risk, BRCA1 and BRCA2
Introduction
Genetic testing in Australia for pathogenic variants in
BRCA1/2 has evolved since the mid-1990s. Although
testing has improved and costs have reduced, it is still
important to offer genetic testing as a priority to families
where it is most likely to be useful. The identification of
a causative pathogenic variant allows for tailored man-
agement of the cancer-affected individual and for pre-
dictive genetic testing for others in the family. Initially,
genetic testing was funded by state health departments,
and individual family cancer clinics (FCCs) determined
the criteria used locally to guide the offer of a BRCA1/2
genetic test to women affected by breast and/or ovarian
cancer. Research generally guided the development of
criteria to be used by FCCs for an offer of testing,
whereby individuals with at least a 10% chance of having
a BRCA1/2 pathogenic variant were offered testing.
However, the Cancer Institute New South Wales con-
vened a national expert group to develop consensus
guidelines on criteria for consideration of BRCA1/2 gen-
etic testing, so that access to such testing would be
equitable across Australia. Guidelines were to be based
on evidence and/or expert opinion in the absence of evi-
dence. The resulting agreed guidelines were then pub-
lished and made available on web-based national clinical
point-of-care guidelines [1], called eviQ [2]. EviQ guide-
lines also cover risk management for carriers of patho-
genic variants and are reviewed regularly and have been
expanded to other hereditary cancer syndromes. Clini-
cians representing all public FCCs in Australia are in-
volved in guideline development, and therefore
notification and dissemination of new or updated guide-
lines is immediately accomplished at all FCCs through
their contributing clinicians. The extent to which clin-
ician advice on risk management according to cancer
genetics guidelines translates into patients taking up this
advice may be affected by many factors including patient
preference and patients’ ability to access risk manage-
ment. Access is affected by geography, local facilities
(medical and investigational), and patient financial and
social resources.
While rigorous controlled trials of cancer risk manage-
ment strategies are few in the hereditary breast/ovarian
cancer field, there is increasing evidence for the use of
specific cancer risk management interventions, such as
preventing ovarian cancer and reducing the risk of
breast cancer associated with BRCA1/2 pathogenic vari-
ants [3]. Individuals at a high risk of developing cancer,
due to an inherited cancer syndrome, provide an ideal
focus for screening and medical/surgical prevention
strategies due to the attractive benefit/risk ratio.
Female carriers of pathogenic variants in BRCA1/2
have a high lifetime risk of breast and ovarian cancer.
For carriers of pathogenic variants in BRCA1, the aver-
age cumulative risks by age 80 years is 72% (95% confi-
dence interval 65–79%) for breast cancer and 44% (36–
53%) for ovarian cancer, and the corresponding esti-
mates for BRCA2 are 69% (61–77%) and 17% (11–25%)
respectively [4]. Carriers of pathogenic variants in
BRCA1/2 may consider risk-reducing bilateral mastec-
tomy to reduce cancer incidence by up to 95% and
breast cancer-specific mortality by 80% [5–7]. Carriers
may also opt for risk-reducing bilateral salpingo-
oophorectomy around age 40 years (after childbearing is
complete). This reduces the risk of ovarian cancer by up
to 95% in carriers of pathogenic variants [8], may reduce
the risk of breast cancer (BRCA2) [9, 10] and reduces
breast/ovarian/all-cause mortality [11]. Women at in-
creased risk of breast cancer, including women with a
BRCA1/2 pathogenic variant, may also consider use of
selective oestrogen receptor modulators (e.g. tamoxifen)
as a risk-reducing strategy. Studies have shown that the
use of such agents can reduce the risk of developing
oestrogen-receptor-positive breast cancer by up to 50%
[12]. Finally, most guidelines relating to carriers of
pathogenic BRCA1/2 variants recommend annual mag-
netic resonance imaging (MRI) in combination with
mammography and/or ultrasound as a screening tool to
maximise the sensitivity of breast cancer screening in
this group [2, 13–16].
However, simply having guidelines agreed by national
experts and published is not sufficient; in order to im-
prove clinical outcomes the appropriate advice (adjusted
for age, health status and personal preference) must be
provided to each woman and to her primary health pro-
fessional. Clinical practice guidelines aim to facilitate
decision-making processes in patient care and have been
shown to be capable of supporting improvements in
quality and consistency in healthcare [17]. However,
merely disseminating guidelines is usually not sufficient
to affect clinical practice [18], and therefore evidence is
required to assess the degree to which guidelines are
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translated into clinical practice [19]. Almost no literature
is currently available on the impact of cancer genetics
clinical practice guidelines. However, we recently
reported on the impact of guidelines on risk manage-
ment for carriers of pathogenic variants in mismatch
repair genes [20]. We found that the rates of documen-
tation of risk management advice in clinic files increased
significantly from pre- to post-guideline publication for
only two out of eight risk management strategies [20],
and the question arises whether risk management advice
is more consistently documented for other familial can-
cer syndromes. In our previous study, we also found
high compliance of carriers post-guideline of risk man-
agement strategies, including colonoscopy (87% compli-
ance) [20]. Similar data are needed for female carriers of
BRCA1/2 pathogenic variants.
This current study addresses this gap in the literature
by investigating two key areas. The first part of the study
investigated the impact of the publication of Australian
clinical practice guidelines on use of BRCA1/2 germline
testing for women with breast and/or ovarian cancer.
The study also assessed documented compliance by cli-
nicians with respect to national risk management guide-
lines for unaffected female BRCA1/2 pathogenic variant
carriers. Furthermore, the study surveyed patients to in-
vestigate their uptake of strategies from the national risk
management guidelines. Specifically, the study aimed to
assess the extent to which carriers adhered to recom-
mended risk management guidelines. Finally, the patient
surveys permitted exploratory questions about perceived
barriers or reasons underlying any failure to undertake
recommended risk management strategies.
Methodology
The design of the study was an uncontrolled before and
after design. Such a design is considered appropriate for
guideline evaluation, because randomised controlled tri-
als are not feasible for practical and ethical reasons [19].
Australia has 18 public familial cancer clinics (FCCs);
their functions vary in relation to coordinating and de-
livering care to carriers of pathogenic BRCA1/2 variants.
FCCs without a risk management service refer patients
back to their non-genetics medical specialist or primary
care physician for ongoing care, while those with an as-
sociated risk management service manage at least some
of the patients themselves. Risk management advice at
FCCs is provided by clinicians with medical qualifica-
tions (clinical geneticists, breast/gynaecological cancer
specialists or oncologists with expertise in familial can-
cer) as well as genetic counsellors, who are not medically
trained. For this study, participation occurred at 12 out
18 of public FCCs (four in Victoria, five in New South
Wales, and one each in South Australia, Western
Australia and Queensland) following approval from the
head of each of the FCCs, who was invited to participate
via an invitation email that described the study.
File audits
Two file audits were undertaken at each FCC to (i)
assess eligibility for BRCA1/2 germline testing against
eviQ cancer genetics guidelines amongst women who
were tested and (ii) document risk management advice
given to unaffected female BRCA1/2 pathogenic variant
carriers. The criteria for eligibility for genetic testing and
the risk management recommendations for carriers are
presented in Tables 1 and 2 respectively.
File audit to investigate use of BRCA1/2 genetic testing
For the file audit to ascertain women’s eligibility for
genetic testing for BRCA1/2, the Queensland FCC did
not participate, because they used a higher minimum
positive predictive value to identify a BRCA1/2 patho-
genic variant (20%) compared to other FCCs (10%) to
determine eligibility for BRCA1/2 testing at the time of
the study. For the audit on reasons for genetic testing,
participating FCCs prepared a list of all women who had
genetic testing during three time periods: July 2008–July
2009 (i.e. before guideline release), July-2010-July 2011
and July 2012–July 2013 (both after guideline release).
Women who self-funded BRCA1/2 genetic testing were
excluded, because genetic testing eligibility guidelines do
not apply to this group. From these lists, up to 32
women per FCC and per assessment time period were
randomly selected. Due to the roll out of the guidelines
at slightly different times at different clinics, the three
assessment time periods were separated by 12-months
periods.
A checklist was completed by the local ICCon co-
ordinator to indicate the reason the woman relating to
the file was offered genetic testing. An example checklist
is provided in Supplementary File 1. Two slightly revised
versions of genetic testing guidelines were published
during the assessment period: Version 1 (June 2010–
February 2011) and Version 2 (October 2011–July 2013),
although there were minimal differences, and appropri-
ate checklists corresponding to each version were used.
The main differences were that Version 2 of the genetic
testing guideline had: (i) a Manchester score [21] cut-off
of 16 instead of 15, and that (ii) the term “serous or
endometroid” was replaced with “invasive non-
mucinous”. If non-compliant, the ICCon co-ordinator
completing the checklist extracted reasons for non-
compliance from clinic files (see Supplementary File 1,
Point 2.f, for a list of potential reasons).
File audit on impact of risk management guidelines
As an initiative of the Inherited Cancer Connect (ICCon)
Partnership, a national database has been established to
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house de-identified data on individuals found to carry a
pathogenic variant in a known hereditary cancer suscep-
tibility gene through all public Australian FCCs. Using
ICCon data, study co-ordinators working in the partici-
pating FCCs prepared lists of all female carriers of
pathogenic variants in BRCA1/2 genes without breast/
ovarian cancer who had undergone predictive testing
and were identified as carriers during the three assess-
ment time periods. We were unable to include enough
carriers for the third time period for the guidelines on
risk management, and hence the files from this period
were not included in the analyses on risk management.
Similar to the genetic testing eligibility audit, a checklist
for each guideline was completed by the local ICCon co-
ordinator to indicate whether the file related to each of
the included carriers documented that the woman was in-
formed about each risk management strategy listed in the
guideline. An example checklist for the risk management
file audit is provided in Supplementary File 2. A file was
deemed concordant with guidelines if the information on
risk management was documented in the files as having
been either provided verbally to the woman during the
consultation or through a letter to the referring doctor
with a copy to the carrier or via a fact sheet given to indi-
vidual. Two revised versions of risk management guide-
lines for BRCA1 were published: Version 1 (July 2011–
June 2012) and Version 2 (July 2012–December 2013).
The two versions did not differ on age-specific advice
about the main risk management strategies of breast and
ovarian cancer screening, surgical prevention and risk-
reducing medication; however they were updated for life-
style advice. Appropriate checklists corresponding to each
version were used.
Interviews with carriers of BRCA1/2 pathogenic variants
An invitation letter was sent by heads of FCCs to those
carriers of BRCA1/2 pathogenic variants included in the
risk management advice file audit to participate in a tele-
phone interview. Participants were given the option of
opting out via mail, phone or fax if they preferred not to
Table 1 Number and percentage of files meeting genetic testing reasons (n = 883)












Manchester score≥ 16a* 170/233 (73) 152/242 (63) 151/249 (61)
BOADICEA score≥ 10b 6/7 (86) 7/13 (54) 10/23 (44)
BRCAPRO score≥ 10b 33/48 (69) 37/57 (65) 27/52 (52)
Individuals with triple negative breast cancer, (age≤ 40 yrs)* 72/280 (26) 22/300 (7) 24/301 (8)
Individuals with isolated high-grade (Grades 2 & 3) invasive, non-mucinous
ovarian, fallopian tube or primary peritoneal cancer (age≤ 70 yrs)*
11/280 (4) 13/300 (4) 20/302 (7)
Individual with high-grade serous or endometroid (or invasive non-mucinous)
ovarian, fallopian tube or primary peritoneal cancer and a family history*
9/280 (3) 19/301 (6) 36/302 (12)
Met at least one criterion 192/243 (79) 217/281 (77) 220/281 (78)
Women who self-funded testing were excluded. *Denominators vary due to missing data. aManchester scores for each woman relating to a file were calculated by
ICCon co-ordinators rather than extracted from files. bDenominator relates to the number of files where score is mentioned













Enrolled in the Treatment Focused Genetic Testing Studyb 0 (0) 3 (3) 0 (0) 3 (1)
Gender imbalance-pedigree includes mostly males 3 (3) 2 (2) 5 (6) 10 (4)
Small family size-not enough people in the pedigree to allow an
estimation of prevalence
2 (2) 7 (7) 4 (4) 13 (5)
There is ovarian cancer in the family 10 (12) 5 (5) 1 (1) 16 (6)
Patient was adopted 3 (3) 1 (1) 1 (1) 5 (2)
Patient did not know about their family history 1 (1) 0 (0) 0 (0) 1 (0)
Patient’s breast cancer diagnosis < 40 years 15 (18) 22 (23) 28 (31) 65 (24)
Other 51 (60) 54 (57) 46 (51) 151 (56)
aMore than one reason could be mentioned per test ordered. Women who self-funded testing were excluded
bTrial offering genetic testing for affected women aged < 50 years with high-risk features
cCount based on responses to open-ended item “Other reasons” in Supplementary File 1
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be contacted. Two weeks after the letters were sent out,
the local ICCon co-ordinator called women who had not
opted out to investigate their uptake of risk management
strategies, using a checklist to record whether or not the
carrier had implemented each of the risk management
strategies. An example of an interview checklist is shown
in Supplementary File 3.
Data analysis
The checklists were completed electronically using the
University of New South Wales survey provider and ana-
lysed by the central study co-ordinator using the statis-
tical software SPSS (Statistical Programme for the Social
Sciences) Version 25. For the files on guidelines for gen-
etic testing use, a Manchester score [21] was calculated
by the local ICCon co-ordinator based on information
from the pedigree (if a Manchester score was not men-
tioned in the file). About 10% of the audited files were
randomly selected and independently rated by the cen-
tral study co-ordinator to calculate inter-rater reliability
of compliance ratings. For the file audit, the files relating
to women were classified as concordant or non-
concordant to guidelines with respect to documented
advice for each risk management strategy. Similarly, for
the interviews, women were classified as concordant or
non-concordant with guidelines with respect to each risk
management strategy, based on their age at the time of
interview. Given risk management guidelines for BRCA1
and BRCA2 pathogenic variant carriers were quite simi-
lar, the data on carriers of BRCA1 and BRCA2 patho-
genic variants were combined for analyses. Chi square
and Kruskal-Wallis tests were performed to compare the
rates of compliance before and after the introduction of
guidelines. Significance level was set at p < 0.05. Reasons
for non-compliance, which were provided using open-
ended response options, were extracted, categorised and
then tallied.
Results
File audit to determine reasons for BRCA1/2 genetic
testing
Interrater reliability coefficients (k statistics) for assessing
individual guidelines were between 0.79–0.87 for reasons
for BRCA1/2 genetic testing, and the overall k statistic was
0.84. A total of 883 files were audited for the genetic test-
ing reason audit over the three time periods. For the 11
participating FCCs, the number of files ranged between 7
and 35 for the pre-guideline period, and between 12 and
35 and between 13 and 35 for the two-years and four-
years post-guideline periods respectively.
Table 1 shows the number of files relating to women
eligible for BRCA1/2 testing against set criteria for test-
ing. Before the release of the guidelines, 79% of the files
met at least one of the criteria, while 21% of files did not
meet any of the criteria. Two- and four-years post-
guideline release, 77 and 78% of files met at least one
genetic testing criterion respectively. The compliance to
genetic testing guidelines was not significantly different
between the three time periods (χ = 0.25, p = 0.88).
Table 2 summarises the reasons indicated in the files
for non-compliance. Table 2 demonstrates that the three
most frequent reasons across the three time periods
taken together were that the patient was diagnosed with
breast cancer under the age of 40 years (24%), there was
ovarian cancer in the family (6%) and small family size
(5%). No reasons for testing were provided for all but 14
women who did not meet guideline-based testing criteria
pre-guideline, while at two- and four-years post-
guideline a reason for testing was documented for all
women who did not meet guideline-based criteria.
File-documented recommendations on risk management
strategies of carriers
Interrater reliability coefficients (k statistics) for asses-
sing documentation of individual guidelines in patient
records were between 0.85–0.94 for risk management of
carriers of BRCA1/2 pathogenic variants and the overall
k statistic was 0.92. A total of 599 files were audited, and
of these, 316 (53%) and 283 (47%) related to carriers of
pathogenic variants in BRCA1 and BRCA2 respectively.
Of these 373 (62%) files were from the time period be-
fore the guidelines were published and 226 (38%) from
the post-guideline time period. For the 12 participating
FCCs, the number of files ranged between 12 and 58 for
the pre-guideline period, and between 6 and 33 and be-
tween 4 and 53 for the two- and four-years post-
guideline periods respectively.
Results of comparisons of clinicians’ recommendations
documented in women’s files on risk management strat-
egies pre- and post-release of guidelines are shown in
Table 3. The rates of documentation of guidelines for 6/
9 risk management items increased significantly from
pre- to post-release of guidelines. These include the
items which have the most significant impact on cancer
risk and mortality, namely risk-reducing mastectomy
and risk-reducing bilateral salpingo-oophorectomy.
Overall documentation of advice around items of risk
management strategies following guideline release
ranged from 29 to 98%. The highest rates of documenta-
tion post-release were for the following recommended
strategies: risk-reducing salpingo-oophorectomy for
ovarian cancer prevention (98%), risk-reducing bilateral
mastectomy (92%), and breast cancer screening in 30- to
50-year-old women (88%). Low rates of documentation
post-release were annual screening in women above 50
years of age (49%); however, 50 and 67% of pre- and
post-guidelines files respectively stated that the patient
was still young and that it would be discussed at an
Meiser et al. Hereditary Cancer in Clinical Practice           (2021) 19:24 Page 5 of 11
appropriate age. Additional analyses showed that
amongst women aged > 50 years, only 30% were docu-
mented as being provided with advice on annual mam-
mography (+/− ultrasound + clinical breast
examination). Also, the lowest rate of documentation
was found for: “If pregnant - no MRI or mammography
and consider ultrasound if pregnant” (29%). However, 62
and 67% of pre- and post-guidelines files respectively
stated that management of screening during pregnancy
was left to the specialist.
Figure 1 shows significant increases from pre- to post-
release of guidelines in documentation of advice on the
following lifestyle factors: exercise (χ2 = 13.96, p < 0.001),
maintaining a reasonable weight (χ2 = 17.83, p < 0.001)
and breastfeeding (χ2 = 20.43, p < 0.001). No significant
changes were observed in documentation of advice on
avoiding post-menopausal HRT after 50 years of age
(χ2 = 1.57, p = 0.48). Despite the increase of the docu-
mentation of lifestyle-related advice, it was below 50%
for all lifestyle factors (Fig. 1) post-guidelines.
Table 3 Number and percentages of files concordant pre- and post-release of guidelines with advice on risk management
strategies provided to carriers











RRBM ≤40 years followed by self-surveillance of chest wall area* 302/365 (83) 206/224 (92) 0.002
Alternatively, in the absence of RRBM, has RRSO been discussed, preferably
≤40 years or before menopause to reduce breast cancer risk?*
307/356 (86) 182/218 (84) 0.37
If breast cancer has been diagnosed in this family < 35 years, has screening been
recommended from 5 years prior to earliest age affected?a
79/128 (62) 42/63 (67) 0.51
30–50 years - annual MRI + MMG (if MRI unavailable, annual MMG + US), consider
6-month interval US +CBE*
257/334 (77) 182/206 (88) 0.001
> 50 years - annual MMG+/− US+ CBE* 138/281(49) 85/175 (49) 0.91
If pregnant - no MRI or MMG, consider US 7/65 (11) 10/34 (29) 0.02
Risk-reducing medication in women > 35 years (such as tamoxifen or raloxifene)* 141/373 (38) 133/226 (59) < 0.001
Ovarian/fallopian tube cancer
RRSO age≤ 40 years (if ovaries present)* 301/356 (85) 213/218 (98) < 0.001
Has the patient been told that screening using serum CA125 and/or transvaginal
ultrasound (TVU) is not recommended?*
202/359 (56) 167/222 (75) < 0.001
*Denominators vary due to missing data. Legend: RRBM Risk-reducing bilateral mastectomy, RRSO Risk-reducing salpingo-oophorectomy, MRI Magnetic resonance
screening, MMG Mammography, US Ultrasound, CBE Clinical breast examination, HRT Hormone replacement therapy. aOnly includes women with a family history
below age 35 years
Fig. 1 Risk management - Comparison of documented lifestyle-related advice for time periods before and after release of guidelines
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Carriers’ uptake of risk management strategies
Of the 599 eligible carriers of pathogenic variants
without a personal history of breast/ovarian cancer
invited to the study, 313 participated in interviews (par-
ticipation rate of 52%). The mean age of the women at
the time of interview was 40 years old (SD = 13.1, range
21 to 90). Table 4 shows the number and percentages of
carriers concordant with each risk management strategy.
For each risk management recommendation, only
women who should have implemented the recommen-
dation based on age are included as the denominator.
For example, for risk-reducing bilateral salpingo-
oophorectomy only women aged 40 years and over at
survey completion who had undergone the risk man-
agement strategy are shown, given that women are
recommended to complete the strategy by age 40.
The strategies with the highest compliance amongst
carriers or awareness post-release of guidelines were
annual MRI + mammography in women 30–50 years
(97%) and annual mammography in women > 50 years
(92%). Of women aged over 40 years, only 41% had a
risk-reducing bilateral mastectomy. Amongst women
aged > 40 years, 75% had a risk-reducing salpingo-
oophorectomy. Amongst women who had not had a
risk-reducing bilateral mastectomy, only 6% took risk-
reducing medication; all of these took tamoxifen, ex-
cept one woman who took anastrozole. Only 58% of
women reported having been told that serum CA125
and/or transvaginal ultrasound is not recommended
as a screening test for ovarian cancer.
Reasons for non-compliance regarding risk management
strategies
Risk-reducing bilateral mastectomy
Amongst women aged < 40 years, 26% had a risk-
reducing bilateral mastectomy, amongst those aged 40–
59 years 49%, and amongst those aged 60+ years 29%.
The most common reasons cited for not having had a
risk-reducing bilateral mastectomy were (all ages): young
age (53%); family not completed yet (44%); pregnancy or
breastfeeding (9%); or being happy to have regular
screening (60%). (Note: more than one reason could be
given).
Risk-reducing salpingo-oophorectomy
Twenty-three percent of women aged < 40 years, 71% of
those aged 40–59 years, and 73% of women aged 60+
years, had a risk-reducing salpingo-oophorectomy. The
most common reasons cited for not having risk-
reducing salpingo-oophorectomy were young age (53%)
and still completing family (44%).
Risk-reducing medication
As we expected few of the women interviewed use risk-
reducing medication, we pre-planned to ask all women
participating in interviews who had not had risk-
reducing bilateral mastectomy: “To what extent do you
agree that each of the following influences your decision
whether or not to use a medicine to reduce your risk of
developing breast cancer?” Attitudes were assessed with
Likert-type response options. Responses are shown in
Table 5.
Seventy-seven percent women agreed ‘somewhat’ or
‘very much’ that the most common reasons affecting
their decision to not take risk-reducing medication was
fear of side-effects, and 57% ‘somewhat’ or ‘very much’
agreed that it was other women’s experiences with it.
Patients’ uptake of lifestyle-related recommendations
Eighty-one percent of patients responded that they exer-
cised, 73% that they maintained a reasonable weight,
94% that they ate a healthy diet, 91% that they avoided
smoking, and 97% that they limited their alcohol intake.
Of the 56 women who reported having had children
since receiving their genetic testing result, 96% reported
breastfeeding.
Table 4 Number and percentages of carriers concordant with risk management strategies based on interviews (n = 313)
Risk management strategy Carriers concordant
n = 313 n (%)
RRBM ≤40 yearsa 70/169 (41)
RRSO ≤40 yearsa 127/169 (75)
30–50 years - annual MRI + MMG (if MRI unavailable, annual MMG + US), consider 6-month interval US +CBEb 92/95 (97)
> 50 years - annual MMG+/− US+ CBEc 46/50 (92)
If pregnant - no MRI or MMG, consider USd 14 /18 (78)
Risk-reducing medication in women (such as tamoxifen or raloxifene)e 6/100 (6)
Has the patient been told that serum CA125 and/or transvaginal ultrasound (TVU) is not recommended? 176/301 (58)
Legend: RRBM Risk-reducing bilateral mastectomy, RRSO Risk-reducing salpingo-oophorectomy, MRI Magnetic resonance screening, MMG Mammography, US
Ultrasound, CBE Clinical breast examination, HRT Hormone replacement therapy. aIncludes only women aged > 40 years as the denominator. bIncludes only
women aged 30 to 50 who have not had RRBM. cIncludes only women > 50 years who have not had RRBM. dIncludes only pregnant women who have not had
RRBM. eIncludes only women who have not had RRBM
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Discussion
We found no significant changes in relation to use of
germline BRCA1/2 testing. The lack of significant
changes may reflect the fact that guidelines were devel-
oped by consensus and reflected current accepted prac-
tice that was already in place when the clinical practice
guidelines were codified. Furthermore, post-guideline
reasons for testing were provided for all tests not meet-
ing guideline-based testing criteria. These findings sug-
gest that current guideline-based testing criteria are too
narrow, and that in practice FCCs apply broader criteria
when offering testing, taking into account family-specific
and individual factors. If these are considered reasonable
factors to guide testing, then consideration should be
given to amending guidelines to ensure equity of access
to testing across the country.
Regarding rates of documentation of risk management
recommendations in files of carriers, rates increased sig-
nificantly from pre- to post-guideline for 6/9 risk man-
agement strategies, and these six included the most
clinically effective strategies, risk-reducing mastectomy
and salpingo-oophorectomy. No statistically significant
increases in documentation were observed for recom-
mendation of: risk-reducing salpingo-oophorectomy for
breast cancer prevention; screening from 5 years prior to
earliest age affected if breast cancer has been diagnosed
in this family < 35 years; and annual breast cancer
screening in carriers from > 50 years. However, regarding
the guidelines on screening from > 50 years, 50 and 67%
of pre-and post-guideline files respectively stated the pa-
tient was young, and that it would be discussed at an ap-
propriate age. Regarding screening during pregnancy, 62
and 67% of pre-and post-guideline files respectively
stated that management of screening during pregnancy
was left to the specialist.
This study shows that the three risk management
strategies with the highest rates of documentation of ad-
vice in files post-release of guidelines (risk-reducing
salpingo-oophorectomy for ovarian cancer prevention,
98%; risk-reducing bilateral mastectomy, 92%; and breast
cancer screening in 30–50 year old women, 88%) are risk
management strategies with a strong evidence base.
These results show that FCC staff prioritise advice on
strategies with proven efficacy. This study also found
low rates of post-guideline documentation of annual
breast cancer screening recommended for women aged
> 50 years (49%); amongst women interviewed aged > 50
years, only 30% women had received advice on annual
mammography. These low rates of documentation of ad-
vice may be because 92% of women aged > 50 years were
already having regular breast screening based on their
family history prior to testing. Further, it is possible that
more carriers were provided with advice on annual
breast screening for women > 50 years than was docu-
mented in their clinic files; however, without documen-
tation, carriers and their doctors have no opportunity to
refer to it for advice. Ensuring that women aged > 50
years receive a recommendation for annual breast
screening consistently, along with improved documenta-
tion, may result in even higher percentages of carriers
taking up annual breast screening. It is important to
highlight that we have not stratified documentation rates
with the age of carriers at the time of delivery of the ad-
vice. Clearly advice, and therefore documentation, may
have been tailored to the specific individual learning
their mutation status and certain risk management strat-
egies omitted from the discussion if they were not age-
or life-stage-appropriate.
The significant increases in concordances pre- to post-
guideline release for the majority of risk management
strategies is in contrast to our findings on concordance
with regard to guidelines on advice related to Lynch syn-
drome, where we found statistically significant increases
in concordance for only two out of eight risk manage-
ment strategies [20]. It might be speculated that for
Lynch syndrome FCC clinicians are more likely to rely
on other non-genetics specialists to provide risk man-
agement advice and management, who may not be as fa-
miliar with the national eviQ guidelines. It is possible
that there are more non-genetics specialists outside
FCCs with the required expertise to oversee risk man-
agement for carriers of BRCA1/2 pathogenic variants,
and/or that FCC staff are reluctant to leave direction for
their risk management to non-genetics specialists lead-
ing them to provide specific risk management advice
more readily compared to that for Lynch syndrome. The
FCC clinicians may feel more confident in providing risk
management advice to BRCA1/2 pathogenic variant









The side-effects of these medicines may affect my decision to take medicine (n = 236) 133 (56) 50 (21) 20 (8) 33 (14)
Other people’s experiences with it (n = 224) 68 (30) 60 (27) 45 (21) 51 (23)
That is also used as a cancer medicine (n = 224) 37 (17) 41 (18) 62 (28) 84 (38)
It is a reminder of your breast cancer risk (n = 227) 25 (11) 23 (10) 44 (19) 135 (60)
aIncludes only women who have not had a risk-reducing mastectomy
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carriers compared to those with variants in MMR genes;
if so, this may be the result of a greater volume of
research being available regarding the efficacy of risk
management in BRCA1/2 pathogenic variant carriers
and/or FCC staff being more experienced in providing
advice to such carriers, given that most patients attend-
ing FCCs are from hereditary breast ovarian cancer fam-
ilies rather than families with Lynch syndrome [22].
When comparing the rates of documented advice and
uptake amongst carriers of risk management strategies,
fortunately, it was found that the rate of uptake of
annual mammography amongst women aged > 50 years
(92%) and uptake of no MRI or mammography in preg-
nant women (78%) was much higher than the advice
documented in the clinic file. This suggests that once
again either the advice was not documented in the clinic
file, or that women received additional recommenda-
tions from other health professionals. We also found
that only 58% of women reported having been told that
serum CA125 and/or transvaginal ultrasound is not rec-
ommended, and this could have resulted in some
women having ovarian cancer screening in the false be-
lief it was beneficial. Fortunately 75% of women > 40
years had risk-reducing salpingo-oophorectomy at the
time of the survey; nonetheless there is still room to im-
prove the delivery and documentation of this important
piece of advice. We did not ask detailed questions why
25% of women > 40 years had not had the surgery. While
some are likely to be in their 40s and not at the right life
stage to contemplate menopause or have other co-
morbidities that render surgery inappropriate, there is
still an important number who are eligible for surgery;
strategies need to be developed to engage this group in
order for them to gain the most clinical benefit from
their genetic diagnosis [23].
We also found that only 6% of women who had
not had a risk-reducing bilateral mastectomy were
taking risk-reducing medication. This low rate of up-
take of risk-reducing medications is consistent with
literature showing that the actual reported uptake of
tamoxifen by women at increased risk for breast
cancer is low e.g. [24–26] However, the low uptake
rate provides an interesting contrast with our find-
ings on the uptake of aspirin in carriers of patho-
genic variants in mismatch repair genes, which
showed that 67% of carriers took aspirin for risk re-
duction [20]. The difference in findings may be re-
lated to aspirin having fewer perceived side-effects
than tamoxifen and tamoxifen having implications
for reproduction in women. In support of this ex-
planation, our study showed that as many as 56% of
women agreed “very much” that the side-effects of
these medicines may affect their decision whether or
not to take them. The similar side-effects (infertility
and menopause) also prevents some women having
risk-reducing salpingo-oophorectomy at an appropri-
ate age [27]. Clearly more research to address and
manage these fears and the side-effects are essential,
if the uptake of risk-reducing medication and
salpingo-oophorectomy is to be optimised.
The study’s strengths and limitations should be noted.
Strengths included the fact that almost all Australian
FCCs participated, leading to low institutional bias and
high representativeness and generalisability of the data,
providing nationwide data on the impact of guidelines
relating to carriers of pathogenic variants in BRCA1/2.
Inter-rater reliabilities of assessments were excellent.
Limitations of the study are a relatively low participation
rate of carriers in the interview study (52%); due to eth-
ical stipulations we were not able to follow up non-
responders more than once. However, similar participa-
tion rates have been reported by other studies using
medical records [28, 29]. Another limitation is that no
data were collected on sociodemographic variables (with
the exception of age) to avoid participant fatigue, limit
the time taken to interview patients, and to comply with
the low-risk ethics approval status of the study. In this
study, we only measured carriers’ compliance with risk
management guidelines; qualitative and quantitative
studies are required to assess the specific barriers to
adoption of guidelines in order to provide the basis for
the development of tailored interventions to address spe-
cific barriers. Finally, the current study did not assess
how carriers were counselled with respect to risk man-
agement strategies, for example, the absolute risk of
breast and/or ovarian cancer related to pathogenic vari-
ants in BRCA1/2, morbidity of risk-reducing surgery,
and the effectiveness of cancer surveillance. The way
carriers are counselled is likely to impact on whether
they have made an informed decision. Future studies
should assess information-giving and counselling behav-
iours during counselling sessions, for example by digit-
ally recording consultations and subjecting recordings to
a rigorous communication analysis [30].
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